Copenhagen’s Samplix has closed the first €25M tranche of a financing round, but the structure matters as much as the size. Only €3M is new capital, with the other €22M arriving as conversions of shareholder convertible bonds.
WLanholding GmbH led, and all major shareholders took part. The round stays open with a €30M target, leaving €5M to fill.
What Xdrop actually solves
Samplix sells Xdrop, a droplet microfluidics platform for functional single-cell analysis. It encapsulates living cells and assay components in stable double-emulsion droplets, letting researchers screen at high throughput against targets conventional methods struggle with, including membrane-bound proteins and reporter-based assays.
The commercial promise is antibody discovery. Xdrop links antibody function to the cell secreting it and to the corresponding sequence, so researchers can identify and recover cells producing antibodies with the desired behaviour. The hard part of antibody work is not finding binders, it is finding ones that do something useful.
A chief executive with a familiar problem
Chief executive Henrik Pfundheller said the investment validates the platform’s value to the antibody discovery community and positions Samplix to scale, deepen biopharma and academic partnerships and improve single-cell workflows.
The fundraise also brings governance. Werner Lanthaler, formerly chief executive of Evotec, will join the board within the year as part of WLan’s investment. He expects Samplix to become a category leader.
European biotech’s quiet revenue model
Danish life science has produced a steady run of tooling companies that sell into global pharma rather than chasing drug programmes of their own. That needs less capital and delivers revenue earlier.
The debt-heavy structure suggests investors want commercial expansion proven before committing fresh equity at a higher valuation. The task now is converting Xdrop evaluations at biopharma partners into recurring platform revenue.
